NGX-1998 Phase 2 Study Data Presented at World Congress on Pain
Multiple Posters on Qutenza ® Presented by Partner Astellas
SAN MATEO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today presented data from its Phase 2 study on NGX-1998 at the 14th World Congress on Pain in Milan, Italy. NGX-1998 is the Company's next generation liquid formulation of prescription-strength capsaicin.The presentation highlighted the Company's Phase 2 clinical trial, a multicenter, placebo-controlled, double-blind trial in postherpetic neuralgia (PHN). The results from the trial indicate that NGX-1998 may be a safe, efficacious and convenient treatment for patients with PHN and other types of neuropathic pain. NeurogesX plans to enable a Phase 3 clinical trial in neuropathic pain by the end of 2012. Stephen J. Peroutka, MD, PhD, Chief Medical Officer of NeurogesX, said, "NGX-1998's liquid formulation allows for easier administration than our already approved capsaicin patch. Our Phase 2 results indicate that with a single, five minute treatment with NGX-1998, subjects experienced pain relief for as long as three months. The data from our Phase 2 study also confirm that NGX-1998 requires no topical anesthetic pre-treatment, making the therapy even more convenient for providers to administer." Patients enrolled in the study had experienced pain for least 6 months following healing of a herpes zoster lesion, and had a Mean Numeric Pain Rating Scale (NPRS) score between 4 to 9, inclusive. Patients were randomized into one of three groups: NGX-1998 capsaicin 20% solution, NGX-1998 capsaicin 10% solution or placebo, according to an unequal allocation scheme of 2:2:1. Based on safety and tolerability results, it was determined that no topical anesthetic pre-treatment was required for treatment with NGX-1998. No patients discontinued the study due to adverse events, and the incidence of adverse events and serious adverse events in patients treated with NGX-1998 were similar to the placebo-treated group.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts